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Pulmonary adenocarcinoma has long intrigued both internists and pulmonologists because it seems to
have unique epidemiologic, pathologic and clinical features. We report a case of multifocal well-differ-
entiated adenocarcinoma, mimicking honeycombing and diffuse inﬂammatory interstitial lung disease.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Pulmonary adenocarcinoma has long intrigued both internists
and pulmonologists because it seems to have unique epidemio-
logic, pathologic and clinical features.We report a case of multifocal
well-differentiated adenocarcinoma, mimicking honeycombing
and diffuse inﬂammatory interstitial lung disease.2. Case: A
52 year old Hispanic non smoker male with no past medical
history presented with persistent dry cough, occasional fever and
dyspnea at rest. The symptoms were gradual in onset and
progressively worsening for about 6 months with no hemoptysis,
night sweats or pleuritic chest pain. Patient admitted to have been
treated with multiple antibiotics by his primary care giver, but
without any improvement in the symptoms. He also had an x-ray
and the Computed Tomography (CT) of the chest 3 months back
which showed diffuse interstitial changes in both the lungs.
Pulmonary function test showed a restrictive pattern. Patient had
also received trials of bronchodilators and steroids with no
improvement. On admission, patient looked dyspneic withital, Bronx, NY.
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rved.respiratory rate of 24/min and pulse of 110. Pulse oxymeter showed
the saturation of 84% on room air and 95% on 100% non re-breather
mask. Examination of chest revealed bilateral diffuse ﬁne crackles.
Other systemic examinations were normal. Chest x-ray showed
diffuse interstitial changes and CT chest showed diffuse distortion
of lung parenchyma with ground glass opacity, honeycombing and
cystic changes. Patient was started on steroids, bronchodilators and
broad-spectrum antibiotics. Initial complete blood count, metabolic
proﬁle, Anti-Nuclear Antibody (ANA), Rheumatoid Factor (RF),
Angiotensin Converting Enzyme (ACE) and alpha-1-antitrypsin
levels were normal. Multiple sputum samples for gram stain and
cultures for bacteria including mycobacterium tuberculosis were
normal. Fiber optic bronchoscopy with bronchial lavage (BAL) and
transbronchial biopsy (TBB) was done. Pathological examination of
the biopsy showedwell-differentiated adenocarcinomawithmixed
bronchoalveolar pattern. Bone scan showed sclerotic thoraco-
lumbar vertebral metastases. Patient was started on chemotherapy
for unresectable stage IV adenocarcinoma.3. Discussion
Because of the unique radiographic features of Bronchoalveolar
Carcinoma (BAC) it is often called the “masquerader”. Bron-
choalveolar carcinoma may classically manifest as an interstitial
lung disease on chest radiograph, it may produce extensive diffuse
pulmonary inﬁltrates that can mimic those with infectious etiolo-
gies.1 Its presentation may be confused with pneumonia or other
inﬂammatory conditions in the lung, and only after a patient fails to
improve a course of antibiotics or corticosteroids does one enter-
tain the diagnosis of pulmonary adenocarcinoma.
Fig. 2. CT chest: Hazy consolidations are seen at both the lung bases representing
acute process.
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shortness of breath. CT of the chest showed diffuse and extensive
cystic changes, with ground glass opacities, honey combing and
distortion of normal lung parenchyma in both the lungs.
Hazy consolidations were seen at both the lung bases representing
acute process. Patient had failed antibiotic therapy and corticoste-
roid therapy multiple times. The differential diagnosis of these
ﬁndings included cryptogenic organizing pneumonia, chronic
eosinophilic pneumonia, hypersensitivity pneumonitis, drug
induced pneumonitis and usual interstitial pneumonia (UIP). But
all these possibilities were ruled out by the absence of hyper-
eosinophilia in the blood and BAL ﬂuid, absence of response to
corticosteroid and absence of response to antibiotics. Also, patient
denied using any drug or any recent treatment apart from antibi-
otics and corticosteroids. Patient also denied any signiﬁcant occu-
pational exposure. Initially, BAC was not thought to be the cause of
this radiographic appearance because pulmonary architectural is
usually preserved in this condition. Finally, the progression of the
disease process with clinical and radiological deterioration led us to
suspect underlying malignant process. The histopathological
specimen obtained from transbronchial biopsy revealed well-
differentiated bronchoalveolar carcinoma along with inﬂammatory
ﬁbrosis and honeycombing.
The World Health Organization classiﬁes lung adenocarcinomas
into acinar, papillary, bronchoalveolar, and mucus-secreting.2 But
this histopathological variant has not been described by the latest
World Health Organization (WHO) classiﬁcation of lung tumors
although rare cases have been reported.3 The exact pathogenesis of
this phenomenon is under study but seems prominent inﬂamma-
tion and ﬁbrosis overshadows tumoral proliferation and
masquerade as a benign reactive process. This can confuse the
physician and can be mistaken as benign inﬂammatory lungs
disease and delay the diagnosis.4 On the contrary, the association of
lung cancer in pre-existing interstitial lung disease has been well
documented. Patient with UIP and pulmonary ﬁbrosis in relation
with collagen vascular and occupational lung diseases can develop
lung carcinoma years after the diagnosis of ILD is established.5,6Fig. 1. CT chest: showing diffuse and extensive cystic changes, with ground glass
opacities, honey combing and distortion of normal lung parenchyma in both the lungs.Bronchoalveolar carcinoma is a distinct clinicopathologic entity
and a subtype of adenocarcinoma that appears to arise from type II
pneumocytes and may manifest radiologically as a solitary
peripheral nodule (SPN), multifocal disease, or a rapidly progress-
ing pneumonic form, which can spread rapidly from one lobe to
another. It usually is located peripherally; the cytology is well-
differentiated and grows along intact alveolar septa (the so-called
“lepidic” growth pattern) but without evidence of vascular or
pleural involvement, and tendency for both aerogenous and
lymphatic spread. Histologically, it is divided into 3 subtypes:
mucinous, nonmucinous and mixed (Figs. 1 and 2).
Clinically, patients may be either symptomatic (usually the ones
that have SPN) or may present with cough and shortness of breath.
Cough may be nonproductive or may be associated with large
amounts of sputum, which is termed as “bronchorrhea” (usually
occurs in the mucinous histological subtype).7
The diagnosis of BAC requires examination of the entire tumor
after resection. Transbronchial biopsy should be not relied upon
since BAC is a non-invasive tumor and diagnosis is dependent upon
demonstration of lepidic growth without invasion of other struc-
tures.8 So even if transbronchial biopsy shows BAC growth pattern,
this does not conﬁrm the diagnosis. However, like in our case, if BAC
presents radiologically with a ground glass appearance or as an
inﬁltrate and the biopsy demonstrated the BAC growth pattern the
diagnosis of BAC may be conﬁrmed, as non BAC adenocarcinoma
does not present as ground glass.8
Treatment depends on the disease stage and extent and may
include surgical resection for the localized form or radiation
therapy with or without chemotherapy in unresectable cases.9 BAC
with epidermal growth factor receptor (EGFR) gene mutation may
beneﬁt from tyrosine kinase inhibitor.10
4. Conclusion
Bronchoalveolar adenocarcinoma should be kept in the differ-
ential diagnosis of any patient presenting with interstitial lung
disease with architectural distortion, particularly if it is not
responding to antibiotics and corticosteroid therapy. This case
V. Pathak, I.S. Hurtado Rendon / Respiratory Medicine CME 4 (2011) 67e69 69highlights the difﬁculties faced in the diagnosis of pulmonary
adenocarcinoma in presence of inﬂammation and ﬁbrosis. It also
reinforces the importance of tissue diagnosis in patients with
Interstitial Lung Disease.
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